ALS Ltd Stock
€11.80
Your prediction
Financial data and news for ALS
sharewise wants to provide you with the best news and tools for ALS, so we directly link to the best financial data sources.
Financials
News
Electromed Posts 17% Gain in Fiscal Q4
Electromed (NYSEMKT:ELMD), a medical device company specializing in airway clearance therapy, reported record financial results for the quarter and fiscal year ended August 26, 2025. The company’s
Clene Posts 70% Revenue Drop in Q2
Clene (NASDAQ:CLNN), a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases, released its second-quarter 2025 earnings on August 14, 2025. The most important
Brainstorm Posts 43% EPS Gain in Q2
Brainstorm Cell Therapeutics (OTC:BCLI), a biotechnology developer focused on neurodegenerative diseases, released its second quarter 2025 results on August 14, 2025. The headline news was a GAAP
Athira (ATHA) Q2 Loss Narrows 74%
Athira Pharma (NASDAQ:ATHA), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx Pharmaceuticals (NASDAQ:AMLX), a biotechnology company focused on treatments for neurodegenerative and endocrine diseases, reported its second quarter 2025 financial results on August 7
North American Niobium and Critical Minerals Corp. Completes Phase 1 Fall Prospecting Program; Carbonatite and Pegmatite Targets Identified Across Québec Properties
- Completion of Fall 2025 Prospecting Program Across Seigneurie, Bardy, Blanchette and Sabot Properties
- Carbonatite Boulders and Pegmatite Zones Identified
- 262
